Skip to main
  1. Stocks
  2. UroGen Pharma
  3. Forecast
URGN

UroGen Pharma (URGN) Stock Forecast & Price Target

UroGen Pharma (URGN) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

UroGen Pharma is supported by a rapidly improving commercial profile, led by 3Q26 Zusduri revenue of $68.0M, up 35% sequentially and above consensus, while total revenue of $89.0M was roughly in line and the company posted its first meaningful operating income of $8.3M. Launch metrics also strengthened materially, with unique prescribers rising to 662, repeat prescribers reaching about 50% of the total, and activated sites increasing to 1,538, suggesting deeper adoption and expanding recurring use. The outlook is further reinforced by a patent extending coverage into July 2044, FDA acceptance of UGN-103 with a June 14, 2027 PDUFA date, and a pipeline that includes LONGVIEW-HR in 4Q26 and UGN-501 in 4Q26, even as lower Jelmyto guidance to about $90M reflects near-term noise rather than structural weakness.

Bears say

UroGen Pharma is vulnerable to multiple fundamental risks because its valuation depends heavily on a narrow commercial base of two approved products, Jelmyto and Zusduri, both sold principally in the United States, leaving it exposed to any slowdown in adoption or reimbursement. As a clinical-stage biotechnology firm, it also faces meaningful R&D and regulatory uncertainty, and any setbacks in development or approval could reduce confidence in its RTGel platform and limit future growth opportunities. The negative outlook is further supported by the possibility of new competitors, lower-than-expected product sales, and dilutive financing, any of which could pressure earnings quality and shareholder value.

UroGen Pharma (URGN) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of UroGen Pharma and is not a guaranteed prediction by Public.com or investment advice.

UroGen Pharma (URGN) Analyst Forecast & Price Prediction

Get the latest UroGen Pharma (URGN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in UroGen Pharma (URGN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About UroGen Pharma (URGN) Forecast

Analysts have given UroGen Pharma (URGN) a Strong Buy based on their latest research and market trends.

According to 5 analysts, UroGen Pharma (URGN) has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

UroGen Pharma (URGN)


UroGen Pharma (URGN) Analyst Forecast & Price Prediction

Get the latest UroGen Pharma (URGN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in UroGen Pharma (URGN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover URGN stock data and trends